Novartis extends leadership in clinical trial data transparency, reinforcing its support of clinical research and innovation - FierceBiotech

"Novartis announced today additional steps to extend its leadership in clinical trial data transparency. Since 2005, and before requirements were in place, Novartis has been voluntarily disclosing summaries of Clinical Study Reports of its innovative medicines on its own website (http://www.novctrd.com). In addition, the company is committed to enhancing Clinical Study Report summaries for all new pivotal studies to include easy to understand consumer language summaries and additional interpretation of data as of the end of 2014. Novartis has long supported data transparency and was the first company to publish positive and negative study results of its innovative medicines within one year of the study completion further enabling clinical research while protecting patient privacy. To date, Novartis has registered 2,720 trials on ClinicalTrials.gov and published 559 trial results on the same site as well as 1,777 clinical study summaries (known as 'redacted clinical study reports'). Researchers can also now request access to patient level data on newly approved innovative medicines in 2014 through the same Idea Point portal as other pharmaceutical companies ..."